149 related articles for article (PubMed ID: 35018845)
1. Daratumumab infusion reaction rates pre- and post-addition of montelukast to pre-medications.
Coffman K; Carstens C; Fajardo S
J Oncol Pharm Pract; 2023 Mar; 29(2):333-337. PubMed ID: 35018845
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab.
Moore DC; Arnall JR; Thompson DL; Martin AL; Robinson J; Ndiaye A; Paul B; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e777-e781. PubMed ID: 32660902
[TBL] [Abstract][Full Text] [Related]
3. Safety of ninety-minute daratumumab infusion.
Lombardi J; Boulin M; Devaux M; Cransac A; Pistre P; Pernot C; Payssot A; Lafon I; Caillot D; Gueneau P
J Oncol Pharm Pract; 2021 Jul; 27(5):1080-1085. PubMed ID: 32865161
[TBL] [Abstract][Full Text] [Related]
4. Retrospective review of accelerated daratumumab administration.
Patel A; Clark S; Espiritu J; Dechen T; Tran Q
J Oncol Pharm Pract; 2022 Jun; 28(4):816-821. PubMed ID: 33866892
[TBL] [Abstract][Full Text] [Related]
5. A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma.
Stakiw J; Kodad S; LeBlanc R; Sebag M; Hay AE; Kukreti V; Côté J; Camacho F; Fu M; Gul E; Reece D
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):484-490. PubMed ID: 37127473
[TBL] [Abstract][Full Text] [Related]
6. Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma.
Bonello F; Rocchi S; Barilà G; Sandrone M; Talarico M; Zamagni E; Scaldaferri M; Vedovato S; Bertiond C; Pavan L; Bringhen S; Cattel F; Zambello R; Cavo M; Mina R
Front Oncol; 2022; 12():851864. PubMed ID: 35359355
[TBL] [Abstract][Full Text] [Related]
7. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
[TBL] [Abstract][Full Text] [Related]
8. 'Fast but not so Furious': Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy.
Davis JA; Youngberg H; Gaffney K; Duco M; Hashmi H
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e680-e684. PubMed ID: 35414476
[TBL] [Abstract][Full Text] [Related]
9. A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting.
Geirnaert M; Howarth J; Martin K; Ricard C; Streilein S; Wasney D; Dao V; Kotb R; Rimmer E; Minuk L
J Oncol Pharm Pract; 2021 Jun; 27(4):907-910. PubMed ID: 33108988
[TBL] [Abstract][Full Text] [Related]
10. Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience.
De Novellis D; Fontana R; Palmieri S; Della Pepa R; Di Perna M; Cetani G; Esposito D; Amendola A; Delle Cave G; Serio B; Morini D; Rizzo M; Mettivier L; Trastulli F; Rocco S; Pagano A; Barbato S; Leone A; La Magna M; Bianco R; Rascato G; Carobene A; Cuffa B; Iannalfo M; Giudice V; Svanera G; Annunziata M; Pizzuti M; Frigeri F; Califano C; Ferrara F; Pane F; Selleri C
Target Oncol; 2023 Nov; 18(6):885-892. PubMed ID: 37747623
[TBL] [Abstract][Full Text] [Related]
11. Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice.
Hamadeh IS; Moore DC; Martin A; Karabinos A; Hill H; Ndiaye A; Robinson JD; Paul BA; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):470-475. PubMed ID: 33785299
[TBL] [Abstract][Full Text] [Related]
12. Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol.
Hamadeh IS; Reese ES; Arnall JR; Kachur E; Martin AL; Schneider M; Friend R; Paul B; Atrash S; Bhutani M; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):526-532.e1. PubMed ID: 32279951
[TBL] [Abstract][Full Text] [Related]
13. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
[TBL] [Abstract][Full Text] [Related]
14. Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.
Nooka AK; Gleason C; Sargeant MO; Walker M; Watson M; Panjic EH; Lonial S
J Oncol Pract; 2018 Jul; 14(7):414-422. PubMed ID: 29996069
[TBL] [Abstract][Full Text] [Related]
15. Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion.
King T; Jagger J; Wood J; Woodrow C; Snowden A; Haines S; Crosbie C; Houdyk K
Asia Pac J Oncol Nurs; 2018; 5(3):270-284. PubMed ID: 29963589
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
[TBL] [Abstract][Full Text] [Related]
17. Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction.
Aykaş F; Karakuş V; Sevindik ÖG
J Oncol Pharm Pract; 2024 Mar; 30(2):397-399. PubMed ID: 37990526
[TBL] [Abstract][Full Text] [Related]
18. Healthcare utilisation and costs associated with adding montelukast to current therapy in patients with mild to moderate asthma and co-morbid allergic rhinitis: PRAACTICAL study.
Dal Negro R; Piskorz P; Vives R; Guilera M; Sazonov Kocevar V; Badia X
Pharmacoeconomics; 2007; 25(8):665-76. PubMed ID: 17640108
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Neuropsychiatric Diagnoses After Montelukast Initiation.
Paljarvi T; Forton J; Luciano S; Herttua K; Fazel S
JAMA Netw Open; 2022 May; 5(5):e2213643. PubMed ID: 35608857
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
